Aleix Prat
Oncology Department OncologistAbout me
Prof. Aleix Prat is currently the Head of the Medical Oncology Department of Hospital Clínic Barcelona (Spain), Tenure-Track Professor of the University of Barcelona and the Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS). He obtained his MD degree in 2003 from the University of Barcelona and completed a medical oncology fellowship in 2008 at Vall d´Hebron Institute of Oncology (VHIO). In 2008, Dr. Prat became a postdoctoral research associate at the Lineberger Comprehensive Cancer Center (University of North Carolina at Chapel Hill, USA) in the Laboratory of Prof. Charles M. Perou. In 2012, he returned to Barcelona as the Head of the Translational Genomics Group at VHIO and later, he moved t
Featured publications
-
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Authors: H J Burstein, G Curigliano, B Thürlimann, W P Weber, P Poortmans 5, M M Regan, H J Senn, E P Winer, M Gnant, Panelists of the St Gallen Consensus Conference.Reference: Ann Oncol. 2021. -
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT
Authors: Chic N, Schettini F, Brasó-Maristany F, Sanfeliu E, Adamo B, Vidal M, Martínez D, Galván P, González-Farré B, Cortés J, Gavilá J, Saura C, Oliveira M, Pernas S, Martínez-Sáez O, Soberino J, Ciruelos E, Carey LA, Muñoz M, Perou CM, Pascual T, Bellet M, Prat A .Reference: Ebiomedicine 2021. -
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Authors: Prat A, Chaudhury A, Solovieff N, Paré L, Martinez D, Chic N, Martínez-Sáez O, Brasó-Maristany F, Lteif A, Taran T, Babbar N, Su F .Reference: Journal Of Clinical Oncology 2021. -
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy
Authors: Pascual T; Fernandez-Martinez A; Tanioka M; Dieci MV; Pernas S; Gavila J; Guarnieri V; Cortes J; Villagrasa P; Chic N; Vidal M; Adamo B; Muñoz M; Griguolo G; Llombart A; Conte P; Oliveira M; Conte B; Paré L; Galvan P; Carey LA; Perou CM; Prat A.Reference: Clinical Cancer Research 2021. -
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer
Authors: Prat A, Tsai YH, Pascual T, Paré L, Adamo B, Vidal M, Brasó-Maristany F, Galván P, Brase JC, Rodrik-Outmezguine V, Johnston S, Ciruelos E, Parker JS .Reference: Clinical Cancer Research 2020. -
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial
Authors: Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, Escrivá-de-Romaní S, Manso L, Adamo B, Martínez E, Cortés J, Vazquez S, Perelló A, Garau I, Melé M, Martínez N, Montaño A, Bermejo B, Morales S, Echarri MJ, Vega E, González-Farré B, Martínez D, Galván P, Canes J, Nuciforo P, Gonzalez X, Prat A .Reference: Clinical Cancer Research 2020. -
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Authors: Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P.Reference: Lancet Oncology 2020. -
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Authors: Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, Sanfeliu E, Schettini F, Conte B, Brasó-Maristany F, Rodríguez A, Martínez D, Galván P, Rodríguez AB, Martinez A, Muñoz M, Prat A .Reference: Breast Cancer Research 2020. -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Authors: Brasó-Maristany F., Griguolo G., Pascual T., Paré L., Nuciforo P., Llombart-Cussac A., Bermejo B., Oliveira M., Morales S., Martínez N., Vidal M., Adamo B., Martínez O., Pernas S., López R., Muñoz M., Chic N., Galván P., Garau I., Manso L., Alarcón J., Martínez E., Gregorio S., Gomis R.R., Villagrasa P., Cortés J., Ciruelos E., Prat A..Reference: Nature Communications 2020. -
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Authors: Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J .Reference: Lancet Oncology 2020.
Featured Projects
-
AACR 2019 - Tailoring systemic treatment of Luminal B breast cancer
Principal investigator: Patricia Galvan, Aleix Prat AparicioFunder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer ResearchCode: BCRF_AACR_18_001Duration: 01/07/2019 - 30/06/2021 -
Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk
Principal investigator: Aleix Prat AparicioFunder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Fundación Quiron Salaud ; Fundación Quirón SaludCode: TERAPIA_AMIGOS_18_01Duration: 11/02/2019 - 10/02/2022 -
Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer
Principal investigator: Aleix Prat AparicioCode: 2018NOVPCC1294Duration: 01/02/2019 - 31/01/2022 -
Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS
Principal investigator: Aleix Prat AparicioCode: AP168952018Duration: 15/06/2018 - 14/06/2021 -
AECC 2017 Predictores moleculares de la respuesta al doble bloqueo de HER2 sin quimioterapia en el cancer de mama HER2-positivo
Principal investigator: Aleix Prat AparicioDuration: 01/11/2017 - 31/12/2019